TriunityCX | ARC Platform
ARC Platform

Real-world evidence
at the point of care.

ARC connects pharmaceutical companies with health systems through structured post-discharge care coordination. It generates the prospective patient data that no claims database provides.

8.1pt
90-Day Adherence
Improvement
4.6pt
30-Day Readmission
Reduction
$1,840
Cost Avoidance
Per Patient
ARC · Cardiovascular · Q1 2025
63.4%
90-Day Adherence
vs 55.3% control
16.8%
30-Day Readmission
vs 21.4% control
1,142
Enrolled
4 Health Systems
Adherence Trend · ARC vs Control · ADH-01
D0 30d 60d 90d ARC 63.4% Control 55.3%
Non-Adherence Barriers · 30-Day · BEH-01
n=477
Cost / Copay
38%
Side Effects
24%
Felt Better
20%
Forgot
18%
Cost barrier rises 38% → 44% by day 60
Cardiovascular
Oncology
Type 2 Diabetes
Respiratory
HIPAA Safe Harbor
30 / 60 / 90-Day Protocol
Pharma-Funded Model
CMS ACCESS Model
The Problem

Post-discharge care is broken.
The data proves it.

The gap between hospital discharge and stable outpatient care is where patients fall through. It is also where the most valuable clinical evidence in pharma goes uncollected.

01
Claims data arrives too late

Pharmacy claims reflect a missed refill 30 to 60 days after the fact. By the time Medical Affairs sees the signal, the readmission window has already opened and the patient is already lost.

02
Nobody captures the why

Claims tell you a patient stopped therapy. They do not tell you it was because the copay hit $160 when the sample supply ran out, or because a side effect was never addressed. That distinction is worth billions in Patient Services spend.

03
Hospitals carry the cost alone

Health systems absorb readmission penalties under HRRP without the infrastructure or funding to run proactive post-discharge outreach. The cost of inaction falls entirely on the hospital.

Our Solution

One program. Two beneficiaries.
Data that didn't exist before.

ARC aligns the incentives of hospitals and pharmaceutical companies around a shared infrastructure and generates evidence neither could produce alone.

Prospective Data Capture

Care coordinators reach patients at 30, 60, and 90 days post-discharge. Adherence status, barriers, copay reach, and side effect type are captured live, not reconstructed from claims months later.

Pharma-Funded Care Coordination

Pharmaceutical partners fund the ARC subscription. Health systems receive structured discharge follow-up and outcomes reporting at zero implementation cost.

Publication-Grade RWE

ARC builds a prospective, discharge-anchored cohort across multiple health systems, structured for peer-reviewed publication and payer dossier submission from day one.

The Platform

Data your teams
can't get anywhere else.

Claims databases tell you what happened. ARC tells you why, while the patient is still in the window where intervention changes the outcome.

See the Dashboard
Data Point
Claims / EHR
ARC Platform
30-day readmission rate
Available
Available
PDC / fill rate
30-60 day lag
Within 30 days
Why patient stopped therapy
Not available
Live call data
Barrier shift 30 to 60 days
Not available
Longitudinal
Copay program awareness rate
Not available
Captured at call
+ 8 additional proprietary metrics
Not available
Available in demo
Health Systems

Cut Readmissions.
Meet CMS Requirements.
No Cost to You.

ARC gives hospitals structured care coordination infrastructure funded entirely through pharmaceutical partnerships. Reduce 30-day readmissions, support CMS ACCESS Model compliance, and improve patient outcomes. There is no implementation cost or additional headcount required.

  • Reduce 30-day readmissions across high-risk DRGs
  • Support CMS ACCESS Model compliance requirements
  • Zero implementation cost, covered by the ARC pharma subscription
  • Structured post-discharge outreach and adherence tracking
  • Outcomes reporting embedded in existing workflows
  • Scalable from single department to system-wide
What You See

Your de-identified outcomes portal

30-Day Readmission Rate
16.8% ↓ from 21.4%
HRRP Penalty Reduction Est.
$218K annualized
7-Day Follow-Up Visit Rate
71.3% ↑ from 44.9%
Top Patient Barrier
Cost / Copay · 41%

Drug, brand, and pharma partner information is not included in the hospital view. All outcomes are attributed to the ARC care coordination program.

Pharma Partners

Real-World Evidence.
At the Point of Care.

ARC gives pharmaceutical companies direct access to de-identified, prospective patient outcome data generated at the point of care, in the post-acute populations that matter most to Medical Affairs, HEOR, Commercial, and Patient Services.

  • Barrier data unavailable in any claims database
  • Copay program awareness and activation funnel by site and payer
  • Prospective side effect distribution for Medical Affairs
  • Publication-grade RWE cohort across multi-site health systems
  • 30/60/90-day longitudinal record anchored to discharge
  • TriunityCX manages all health system relationships
Your Teams

Who uses ARC data

Medical Affairs
Prospective tolerability data, PRO measures, RWE publication pipeline
HEOR / RWE
Budget impact models, cost-effectiveness inputs, payer dossiers
Patient Services
Copay awareness and activation funnel diagnostics by site
Market Access / Commercial
Site-level performance, value-based contract evidence, payer narratives
How It Works

Three data capture intervals.
Ongoing patient contact.

Care coordinators maintain contact with patients throughout the 90-day window. The 30, 60, and 90-day calls are structured data capture points, not the only interactions.

01

Enrolled at Discharge

Diagnosis, payer, demographics, and baseline data recorded. Call schedule set.

02

Ongoing Outreach + Structured Capture

Coordinators maintain contact throughout. Formal data recorded at 30, 60, and 90-day intervals.

03

Hospital Outcomes Merged

Readmissions, ED visits, and follow-up completion added quarterly from the health system.

04

Dashboard Delivered

Pharma receives the full ARC view. Hospitals receive a de-identified outcomes-only portal.

Discharge
Enrollment
Baseline data · Call schedule set
Day 30 · Structured Data Capture
First Call
Adherence · Barriers · First fill · Side effects
Day 60 · Structured Data Capture
Second Call
Barrier shift · Copay activation · ED visits
Day 90 · Structured Data Capture
Third Call
PDC · Persistence · Final barrier profile
Output
ARC Dashboard
Pharma full view · Hospital de-identified view
Program Performance

Outcomes that move both sides.

Cardiovascular benchmark figures across the ARC network. Compared to same-site historical control with propensity score matching.

ADH-01
63.4%
+8.1 pts vs control
90-Day Medication Adherence
READ-01
16.8%
−4.6 pts vs control
30-Day All-Cause Readmission
ADH-04
63.2%
+12.4 pts vs control
First Fill Rate · 7-Day Window
FIN-01
$1,840
per enrolled patient
Readmission Cost Avoidance
READ-05
71.3%
+26.4 pts vs control
7-Day Post-Discharge Follow-Up
ADH-06
58.9%
+11.2 pts vs control
PDC ≥80% Rate
Metric
Type
In Claims?
Barrier shift 30 to 60 days
ARC Only
✗ No
+ 8 additional proprietary metrics
ARC Only
✗ No
PDC / Proportion of Days Covered
Standard
✓ 30-60d lag
30-day all-cause readmission
Standard
✓ Available
7-day post-discharge follow-up
Standard
✓ Available

The barrier shift metric is the one we share publicly. The remaining proprietary metrics are available in the demo.

Evidence Architecture

A proprietary data layer.
Built into every call.

ARC tracks standard industry metrics every pharma team already knows. On top of those, it captures a set of call-derived data points that do not exist in any claims database, EHR, or published RWE study.

The standard metrics confirm the program works. The proprietary layer explains why patients fail and where the money to fix it should go.

Our Mission

Better outcomes for patients.
Better evidence for science.

We believe the gap between discharge and recovery is where the healthcare system most fails patients, and where the most important clinical evidence goes uncollected.

Patient Outcomes

No patient left behind at discharge

Structured post-discharge follow-up should be standard care for every high-risk patient. ARC funds that infrastructure through pharmaceutical partnerships so hospitals do not have to choose between quality and cost.

Evidence Quality

Prospective over retrospective, always

The healthcare system has enough retrospective claims data. What it lacks is prospective, behavioral, discharge-anchored evidence captured at the moment of the patient decision. ARC generates that data at scale.

Aligned Incentives

Hospitals and pharma working toward the same outcome

ARC is built on the belief that health systems and pharmaceutical companies share a fundamental interest in patient adherence and recovery, and the right infrastructure can make both benefit from the same program.

See what ARC can do
for your pipeline.

Schedule a conversation about your therapeutic area, your evidence gaps, and how ARC generates the data your Medical Affairs, HEOR, Commercial, and Patient Services teams need from the point of care.

Book a Demo
For Pharma Teams

Medical Affairs, HEOR, RWE, Patient Services, Market Access, and Commercial. The demo is built around your therapeutic area and team priorities.

For Health Systems

CMOs, CNOs, and care coordination leaders. See the hospital portal, the discharge protocol, and the outcomes dashboard built for your team.

HIPAA Compliant

All data de-identified per HIPAA Safe Harbor. BAAs executed with all health system partners. Enterprise-ready data governance.